Geron Stock Performance
| GERN Stock | USD 2.93 0.09 2.98% |
The company retains a Market Volatility (i.e., Beta) of 0.13, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Geron's returns are expected to increase less than the market. However, during the bear market, the loss of holding Geron is expected to be smaller as well. At this point, Geron has a negative expected return of -0.54%. Please make sure to check out Geron's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Geron performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Geron has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 57.2 M |
Geron |
Geron Relative Risk vs. Return Landscape
If you would invest 412.00 in Geron on November 9, 2024 and sell it today you would lose (119.00) from holding Geron or give up 28.88% of portfolio value over 90 days. Geron is currently does not generate positive expected returns and assumes 2.5309% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Geron, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Geron Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Geron's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Geron, and traders can use it to determine the average amount a Geron's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.215
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GERN |
Estimated Market Risk
| 2.53 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.54 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Geron is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Geron by adding Geron to a well-diversified portfolio.
Geron Fundamentals Growth
Geron Stock prices reflect investors' perceptions of the future prospects and financial health of Geron, and Geron fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Geron Stock performance.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (1.00) % | ||||
| Current Valuation | 1.51 B | ||||
| Shares Outstanding | 604.5 M | ||||
| Price To Earning | (12.48) X | ||||
| Price To Book | 6.02 X | ||||
| Price To Sales | 61.93 X | ||||
| Revenue | 237 K | ||||
| EBITDA | (174.78 M) | ||||
| Cash And Equivalents | 219.29 M | ||||
| Cash Per Share | 0.58 X | ||||
| Total Debt | 85.9 M | ||||
| Debt To Equity | 0.39 % | ||||
| Book Value Per Share | 0.48 X | ||||
| Cash Flow From Operations | (167.74 M) | ||||
| Earnings Per Share | (0.32) X | ||||
| Total Asset | 394.08 M | ||||
| Retained Earnings | (1.6 B) | ||||
| Current Asset | 115.89 M | ||||
| Current Liabilities | 6.63 M | ||||
About Geron Performance
By examining Geron's fundamental ratios, stakeholders can obtain critical insights into Geron's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Geron is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company was incorporated in 1990 and is headquartered in Foster City, California. Geron Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.Things to note about Geron performance evaluation
Checking the ongoing alerts about Geron for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Geron help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Geron generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 237 K. Net Loss for the year was (184.13 M) with loss before overhead, payroll, taxes, and interest of (82.9 M). | |
| Geron currently holds about 219.29 M in cash with (167.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.58. | |
| Over 86.0% of the company shares are owned by institutional investors |
- Analyzing Geron's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Geron's stock is overvalued or undervalued compared to its peers.
- Examining Geron's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Geron's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Geron's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Geron's stock. These opinions can provide insight into Geron's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.